Quantum Genomics (ALQGC.PA) Stock Price

Quantum Genomics Price

Euronext·CLOSED
0.07EUR+0.00 (+0.00 %)
Market closed

Revenue at Quantum Genomics has contracted by 4.5% per year over the past 15 years to 10,100.00 EUR. For Quantum Genomics, the net margin of -31,396.0% is up versus -62,738.3% a few years ago. The consensus 12-month price target for Quantum Genomics is 10.20 EUR, about 14,047.0% above where the stock trades today. Of 7 analysts, 0 rate the stock a buy — an overall Sell consensus.

Quantum Genomics stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Quantum Genomics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Quantum Genomics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Quantum Genomics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Quantum Genomics Stock Price History
DateQuantum Genomics Price
7/30/20260.07 EUR
7/29/20260.07 EUR
7/28/20260.07 EUR
7/27/20260.07 EUR
7/24/20260.07 EUR
7/23/20260.07 EUR
7/22/20260.07 EUR
7/21/20260.07 EUR
7/20/20260.07 EUR
7/17/20260.07 EUR
7/16/20260.07 EUR
7/15/20260.07 EUR
7/14/20260.07 EUR
7/13/20260.07 EUR
7/10/20260.07 EUR
7/9/20260.07 EUR
7/8/20260.07 EUR
7/7/20260.07 EUR
7/6/20260.07 EUR
7/3/20260.07 EUR
7/2/20260.07 EUR
7/1/20260.07 EUR
6/30/20260.07 EUR
6/29/20260.07 EUR
6/26/20260.07 EUR
6/25/20260.07 EUR
6/24/20260.07 EUR
6/23/20260.07 EUR
6/22/20260.07 EUR
6/19/20260.07 EUR
6/18/20260.07 EUR
6/17/20260.07 EUR
6/16/20260.07 EUR
6/15/20260.07 EUR
6/12/20260.07 EUR
6/11/20260.07 EUR
6/10/20260.07 EUR
6/9/20260.07 EUR
6/8/20260.07 EUR
6/5/20260.07 EUR
6/4/20260.07 EUR
6/3/20260.07 EUR
6/2/20260.07 EUR
6/1/20260.07 EUR
5/29/20260.07 EUR
5/28/20260.07 EUR
5/27/20260.07 EUR
5/26/20260.07 EUR
5/25/20260.07 EUR
5/22/20260.07 EUR
5/21/20260.07 EUR
5/20/20260.07 EUR
5/19/20260.07 EUR
5/18/20260.07 EUR
5/15/20260.07 EUR
5/14/20260.07 EUR
5/13/20260.07 EUR
5/12/20260.07 EUR
5/11/20260.07 EUR
5/8/20260.07 EUR
5/7/20260.07 EUR
5/6/20260.07 EUR
5/5/20260.07 EUR
5/4/20260.07 EUR
4/30/20260.07 EUR
4/29/20260.07 EUR
4/28/20260.07 EUR
4/27/20260.07 EUR
4/24/20260.07 EUR
4/23/20260.07 EUR
4/22/20260.07 EUR
4/21/20260.07 EUR
4/20/20260.07 EUR
4/17/20260.07 EUR
4/16/20260.07 EUR
4/15/20260.07 EUR
4/14/20260.07 EUR
4/13/20260.07 EUR
4/10/20260.07 EUR
4/9/20260.07 EUR
4/8/20260.07 EUR
4/7/20260.07 EUR
4/2/20260.07 EUR
4/1/20260.07 EUR
3/31/20260.07 EUR
3/30/20260.07 EUR
3/27/20260.07 EUR
3/26/20260.07 EUR
3/25/20260.07 EUR
3/24/20260.07 EUR
3/23/20260.07 EUR
3/20/20260.07 EUR
3/19/20260.07 EUR
3/18/20260.07 EUR
3/17/20260.07 EUR
3/16/20260.07 EUR
3/13/20260.07 EUR
3/12/20260.07 EUR
3/11/20260.07 EUR
3/10/20260.07 EUR
3/9/20260.07 EUR
3/6/20260.07 EUR
3/5/20260.07 EUR
3/4/20260.07 EUR
3/3/20260.07 EUR
3/2/20260.07 EUR
2/27/20260.07 EUR
2/26/20260.07 EUR
2/25/20260.07 EUR
2/24/20260.07 EUR
2/23/20260.07 EUR
2/20/20260.07 EUR
2/19/20260.07 EUR
2/18/20260.07 EUR
2/17/20260.07 EUR
2/16/20260.07 EUR
2/13/20260.07 EUR
2/12/20260.07 EUR
2/11/20260.07 EUR
2/10/20260.07 EUR
2/9/20260.07 EUR
2/6/20260.07 EUR
2/5/20260.07 EUR
2/4/20260.07 EUR
2/3/20260.07 EUR
2/2/20260.07 EUR
1/30/20260.07 EUR
1/29/20260.07 EUR
1/28/20260.07 EUR
1/27/20260.07 EUR
1/26/20260.07 EUR
1/23/20260.07 EUR
1/22/20260.07 EUR
1/21/20260.07 EUR
1/20/20260.07 EUR
1/19/20260.07 EUR
1/16/20260.07 EUR
1/15/20260.07 EUR
1/14/20260.07 EUR
1/13/20260.07 EUR
1/12/20260.07 EUR
1/9/20260.07 EUR
1/8/20260.07 EUR
1/7/20260.07 EUR
1/6/20260.07 EUR
1/5/20260.07 EUR
1/2/20260.07 EUR
12/31/20250.07 EUR
12/30/20250.07 EUR
12/29/20250.07 EUR
12/24/20250.07 EUR
12/23/20250.07 EUR
12/22/20250.07 EUR
12/19/20250.07 EUR
12/18/20250.07 EUR
12/17/20250.07 EUR
12/16/20250.07 EUR
12/15/20250.07 EUR
12/12/20250.07 EUR
12/11/20250.07 EUR
12/10/20250.07 EUR
12/9/20250.07 EUR
12/8/20250.07 EUR
12/5/20250.07 EUR
12/4/20250.07 EUR
12/3/20250.07 EUR
12/2/20250.07 EUR
12/1/20250.07 EUR
11/28/20250.07 EUR
11/27/20250.07 EUR
11/26/20250.07 EUR
11/25/20250.07 EUR
11/24/20250.07 EUR
11/21/20250.07 EUR
11/20/20250.07 EUR
11/19/20250.07 EUR
11/18/20250.07 EUR
11/17/20250.07 EUR
11/14/20250.07 EUR
11/13/20250.07 EUR
11/12/20250.07 EUR
11/11/20250.07 EUR
11/10/20250.07 EUR
11/7/20250.07 EUR
11/6/20250.07 EUR
11/5/20250.07 EUR
11/4/20250.07 EUR
11/3/20250.07 EUR
10/31/20250.07 EUR
10/30/20250.07 EUR
10/29/20250.07 EUR
10/28/20250.07 EUR
10/27/20250.07 EUR
10/24/20250.07 EUR
10/23/20250.07 EUR
10/22/20250.07 EUR
10/21/20250.07 EUR
10/20/20250.07 EUR
10/17/20250.07 EUR
10/16/20250.07 EUR
10/15/20250.07 EUR
10/14/20250.07 EUR
10/13/20250.07 EUR
10/10/20250.07 EUR
10/9/20250.07 EUR
10/8/20250.07 EUR
10/7/20250.07 EUR
10/6/20250.07 EUR
10/3/20250.07 EUR
10/2/20250.07 EUR
10/1/20250.07 EUR
9/30/20250.07 EUR
9/29/20250.07 EUR
9/26/20250.07 EUR
9/25/20250.07 EUR
9/24/20250.07 EUR
9/23/20250.07 EUR
9/22/20250.07 EUR
9/19/20250.07 EUR
9/18/20250.07 EUR
9/17/20250.07 EUR
9/16/20250.07 EUR
9/15/20250.07 EUR
9/12/20250.07 EUR
9/11/20250.07 EUR
9/10/20250.07 EUR
9/9/20250.07 EUR
9/8/20250.07 EUR
9/5/20250.07 EUR
9/4/20250.07 EUR
9/3/20250.07 EUR
9/2/20250.07 EUR
9/1/20250.07 EUR
8/29/20250.07 EUR
8/28/20250.07 EUR
8/27/20250.07 EUR
8/26/20250.07 EUR
8/25/20250.07 EUR
8/22/20250.07 EUR
8/21/20250.07 EUR
8/20/20250.07 EUR
8/19/20250.07 EUR
8/18/20250.07 EUR
8/15/20250.07 EUR
8/14/20250.07 EUR
8/13/20250.07 EUR
8/12/20250.07 EUR
8/11/20250.07 EUR
8/8/20250.07 EUR
8/7/20250.07 EUR
8/6/20250.07 EUR
8/5/20250.07 EUR
Access this data via the Eulerpool API
Get Free API Key

Quantum Genomics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
0.00 EUR
-10.76 M EUR
-9.08 M EUR
Jan 1, 2020
1.20 M EUR
-13.86 M EUR
-11.54 M EUR
Jan 1, 2021
116,200.00 EUR
-19.19 M EUR
-16.56 M EUR
Jan 1, 2022
605,000.00 EUR
-30.08 M EUR
-24.94 M EUR
Jan 1, 2023
10,100.00 EUR
-3.14 M EUR
-3.17 M EUR
Jan 1, 2024
0.00 EUR
-1.47 M EUR
-8.89 M EUR
Jan 1, 2025 (e)
153.45 M EUR
350.00 M EUR
565.23 M EUR
Jan 1, 2026 (e)
283.39 M EUR
875.00 M EUR
1.41 B EUR

Quantum Genomics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 5, 2026, 2:20 AM
 
REVENUEM EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEB EUR
NET INCOME GROWTH%
SHARESM
201120122013201420152016201720182019202020212022202320242025e2026e
–––––––––1.00––––153.00283.00
–––––––––––––––84.97
–––––––––-1,200.00––––-0.65-0.35
-1.00-1.00-1.00-1.00-2.00-4.00-7.00-10.00-7.00-12.00-18.00-28.00-1.00-1.00-1.00-1.00
-1.00-1.00-1.00-2.00-4.00-6.00-10.00-13.00-10.00-13.00-19.00-30.00-3.00-1.00350.00875.00
–––––––––-1,300.00––––228.76309.19
–––––-0.01-0.01-0.01-0.01-0.01-0.02-0.02–-0.010.571.41
–––100.0050.0066.6780.0022.22-18.1822.2245.4550.00-87.50166.67-7,162.50150.09
3.403.664.114.816.938.3910.9915.7718.0626.7127.4434.8634.8669.7169.7169.71
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Quantum Genomics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Quantum Genomics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Quantum Genomics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Quantum Genomics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Quantum Genomics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Quantum Genomics stock margins

The Quantum Genomics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Quantum Genomics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Quantum Genomics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
-14,148.52 %
- %
- %
Jan 1, 2020
-1,005.86 %
-1,151.55 %
-958.68 %
Jan 1, 2021
-15,782.62 %
-16,512.05 %
-14,247.59 %
Jan 1, 2022
-4,776.41 %
-4,972.43 %
-4,121.57 %
Jan 1, 2023
-14,148.52 %
-31,062.38 %
-31,396.04 %
Jan 1, 2024
-14,148.52 %
- %
- %
Jan 1, 2025 (e)
-14,148.52 %
228.09 %
368.35 %
Jan 1, 2026 (e)
-14,148.52 %
308.76 %
498.63 %

Quantum Genomics Stock Revenue, EBIT, Earnings per Share

The Quantum Genomics earnings per share therefore indicates how much revenue Quantum Genomics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2019
0.00 EUR
-0.60 EUR
-0.50 EUR
Jan 1, 2020
0.05 EUR
-0.52 EUR
-0.43 EUR
Jan 1, 2021
0.00 EUR
-0.70 EUR
-0.60 EUR
Jan 1, 2022
0.02 EUR
-0.86 EUR
-0.72 EUR
Jan 1, 2023
0.00 EUR
-0.09 EUR
-0.09 EUR
Jan 1, 2024
0.00 EUR
-0.02 EUR
-0.13 EUR
Jan 1, 2025 (e)
2.20 EUR
5.02 EUR
8.11 EUR
Jan 1, 2026 (e)
4.07 EUR
12.55 EUR
20.27 EUR

Quantum Genomics business model & stock analysis

Quantum Genomics SA is a French biotechnology company focused on the discovery and development of novel therapies for the treatment of cardiovascular diseases. The company was founded in 2005 in Grenoble, France, where its headquarters are still located. Over 25 employees are currently working on the development of new drugs. The business model of Quantum Genomics SA is based on the research and development of new and innovative solutions for the cardiovascular disease market. The company focuses on a new class of drugs that target the brain to lower blood pressure and treat certain cardiovascular diseases. The goal of these new therapies is to improve the effectiveness of existing treatment methods by directly addressing the causes of the disease. Quantum Genomics SA has established partnerships with renowned research institutes and universities. The collaboration with these institutions aims to accelerate and intensify the research and development of new drugs. Through this collaboration, the company will be able to develop new solutions and therapies to treat cardiovascular diseases at a faster pace. The company is currently working on two main products: Firibastat and the QT-Glutamylcyclotransferase inhibitor. Firibastat is an oral medication developed for the treatment of hypertension. The QT-Glutamylcyclotransferase inhibitor is another medication that is intended to lower blood pressure. These are promising new solutions that can enable Quantum Genomics SA to play a significant role in the cardiovascular disease market. The products of Quantum Genomics SA aim to treat cardiovascular diseases better and more effectively by directly targeting the brain. This aims to reduce the risk of serious complications and side effects that may occur with conventional medications. In recent years, Quantum Genomics SA has received several awards, including the "Innovation Prize" from the French government. These awards demonstrate that the company is on the right track and achieving its goals. Overall, Quantum Genomics SA has a promising business model based on the development of new therapies for the treatment of cardiovascular diseases. With collaborations with renowned research institutes and the development of promising new products, the company is well-positioned to be successful and make significant progress in the growing market of cardiovascular diseases.

Quantum Genomics SWOT Analysis

Strengths

Quantum Genomics SA is a leading biotechnology company specializing in the development of innovative drugs targeting cardiovascular diseases. The company has a strong scientific and research background, enabling them to create unique and effective drug candidates. Their expertise in the field puts them at a competitive advantage.

Quantum Genomics SA has formed strategic partnerships and collaborations with renowned academic institutions and industry leaders. This allows the company to access a wide range of resources, knowledge, and expertise, enhancing their research and development capabilities.

The company has successfully developed a proprietary technology platform that enables the identification and optimization of drug candidates. This platform provides Quantum Genomics SA with a strong intellectual property portfolio, giving them exclusivity over their innovative drug discoveries.

Weaknesses

Quantum Genomics SA may face challenges in the commercialization of their drug candidates. The pharmaceutical industry is highly competitive, and gaining market acceptance and market share can be a lengthy and costly process. This could potentially impact the company's revenue and financial performance.

Another weakness is the company's reliance on external funding sources to support their research and development initiatives. This exposes Quantum Genomics SA to potential funding constraints, making it crucial for them to secure additional investments or partnerships to sustain their operations and growth.

Opportunities

The market for cardiovascular drugs is continuously growing, presenting significant opportunities for Quantum Genomics SA. With their unique and innovative drug candidates, the company has the potential to tap into this market and address unmet medical needs, potentially capturing a substantial market share.

Quantum Genomics SA can explore strategic partnerships with major pharmaceutical companies to accelerate the commercialization and distribution of their drug candidates. Collaborations with established industry players can provide the necessary resources and expertise to navigate regulatory hurdles and reach a wider patient population.

The company can also focus on expanding their product pipeline by leveraging their technology platform and scientific expertise. This can enable Quantum Genomics SA to diversify their drug portfolio, targeting additional cardiovascular indications or exploring applications in other therapeutic areas.

Threats

The biotechnology industry is subject to stringent regulatory requirements and uncertainties. Quantum Genomics SA must navigate through the complex regulatory landscape, ensuring compliance and addressing any potential safety or efficacy concerns that may arise during the drug development process.

Competition is another major threat for the company. As the cardiovascular drug market continues to attract attention, other biotech firms, pharmaceutical giants, and generic drug manufacturers may enter the market with similar or even superior drug candidates, intensifying competition and potentially impacting Quantum Genomics SA's market position.

Economic factors, including changes in healthcare policies, reimbursement systems, and pricing pressures, can also pose challenges to Quantum Genomics SA's financial performance. The company must stay abreast of market dynamics and adapt their strategies accordingly to remain competitive.

Quantum Genomics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Quantum Genomics historical P/E ratio, EBIT multiple, and P/S ratio

Quantum Genomics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Quantum Genomics shares outstanding

The number of shares of Quantum Genomics was 69.71 M in 2025. This indicates how many shares Quantum Genomics is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2019
18.06 M Stocks
Jan 1, 2020
26.71 M Stocks
Jan 1, 2021
27.44 M Stocks
Jan 1, 2022
34.86 M Stocks
Jan 1, 2023
34.86 M Stocks
Jan 1, 2024
69.71 M Stocks
Jan 1, 2025 (e)
69.71 M Stocks
Jan 1, 2026 (e)
69.71 M Stocks

Quantum Genomics stock splits

In Quantum Genomics's history, there have been no stock splits.

Current Quantum Genomics forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
5.26 %
Buy
0.00 % (0)
Hold
28.57 % (2)
Sell
71.43 % (5)
12M Price Target
10.20
Last Price
0.07
Currency
EUR
12M Return Potential
14,047.02 %
LTM Return
0 %

Quantum Genomics Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
10/1/2020-0.32EUR-0.00EUR-2020 Q2

Quantum Genomics shareholder structure

% Name
5.80143%
Otium Capital
Otium Capital
1.10159%
Gulf Pharmaceutical Industries Julphar Co PJSC
Gulf Pharmaceutical Industries Julphar Co PJSC
1.08593%
Milon (Jean-Philippe)
Milon (Jean-Philippe)
1.00425%
Segard (Lionel)
Segard (Lionel)
0.16125%
Quantum Genomics SA Management
Quantum Genomics SA Management

Quantum Genomics Executives and Management Board

3 members · avg. age 51 · 0 % women

Management

MB

Mr. Mathieu Bigois

Chairman of the Board, Chief Executive Officer · since 2024

–

Board of Directors

LN

Mr. Laurent De Narbonne (65)

Director

–
PG

Mr. Pascal Ghoson (36)

Director

–

Frequently asked questions about Quantum Genomics

Quantum Genomics SA is primarily present in multiple countries and regions. The company has a global presence with a significant focus on key markets such as the United States, Europe, and Asia. Quantum Genomics SA operates in various countries within these regions, including France, the United Kingdom, Germany, Belgium, Switzerland, China, Japan, and South Korea. With its expanding international footprint, Quantum Genomics SA aims to reach a wide range of markets and capitalize on the global potential for its innovative pharmaceutical solutions.

The business model of Quantum Genomics SA is focused on developing treatments for cardiovascular diseases and hypertension. By leveraging its unique expertise in the field of brain aminopeptidases and its understanding of their role in cardiovascular diseases, Quantum Genomics aims to create innovative and effective therapies. The company's approach involves developing drugs that target specific brain aminopeptidases, inhibiting their activity and ultimately reducing blood pressure. Through its research and development efforts, Quantum Genomics aims to provide patients with improved treatment options and contribute to the advancement of cardiovascular medicine.

Quantum Genomics SA is primarily active in the pharmaceutical industry.

The main competitors of Quantum Genomics SA in the market include pharmaceutical companies like Novartis AG, Pfizer Inc., and AstraZeneca PLC. These companies actively participate in the development and commercialization of cardiovascular and central nervous system (CNS) medicines, similar to Quantum Genomics SA. With its innovative approach in developing drugs targeting hypertension and heart failure, Quantum Genomics SA competes with established pharmaceutical players to expand its market presence. By leveraging its distinctive technology and scientific expertise, Quantum Genomics SA aims to gain a competitive edge and capture a significant market share in the cardiovascular and CNS therapeutic areas.

Quantum Genomics SA is a leading biopharmaceutical company specializing in the development of innovative treatments for cardiovascular diseases. Founded in 2005, Quantum Genomics has made significant strides in the field of hypertension and heart failure research. With a focus on pioneering new therapeutic approaches, the company has developed QGC001, a first-in-class medication targeting brain aminopeptidase A (APA). By leveraging its expertise in molecular and cellular pharmacology, Quantum Genomics aims to revolutionize cardiovascular treatments and improve patient outcomes. With a dedicated team and a strong pipeline, Quantum Genomics SA continues to make advancements in its pursuit of breakthrough solutions for cardiovascular health.

Quantum Genomics SA, a leading biopharmaceutical company, has achieved several significant milestones. The company successfully completed Phase IIb clinical trials for its flagship drug, Firibastat, demonstrating its effectiveness in treating hypertension and heart failure. Quantum Genomics also secured strategic partnerships with renowned pharmaceutical companies, accelerating the drug's development and expanding its market reach. Furthermore, the company obtained regulatory approvals in Europe and the United States, paving the way for commercialization. Quantum Genomics SA's dedication to innovation and clinical excellence has positioned it as a key player in the field of cardiovascular diseases, with promising prospects for future growth and success.

Quantum Genomics SA represents values of innovation, dedication, and excellence in the field of cardiovascular diseases. The company's corporate philosophy revolves around their commitment to developing breakthrough therapies for patients suffering from high blood pressure and heart failure. Quantum Genomics SA aims to provide effective solutions through their cutting-edge research and pharmaceutical advancements. With a focus on addressing unmet medical needs, they strive to improve the quality of life for individuals worldwide. By combining scientific expertise and a patient-centric approach, Quantum Genomics SA is dedicated to making a significant impact on cardiovascular healthcare.

Analysts currently set an average price target of 10.20 EUR for the Quantum Genomics stock (median: 10.20 EUR), implying +14,047.0 % versus the latest price. The consensus is based on 7 analyst ratings.

Quantum Genomics Analyst Price Targets 2026

7 analysts currently rate the Quantum Genomics stock: 0 recommend buying, 2 holding and 5 selling. For 2026, analysts expect Quantum Genomics to generate revenue of 283.39 M EUR and earnings per share of 20.27 EUR.

Quantum Genomics Analyst Price Targets 2026

The Quantum Genomics share (ALQGC.PA) is listed on 6 stock exchanges, including: Frankfurt (2QG.F), München (2QG.MU), London (0D1J.L), Paris (ALQGC.PA).

Quantum Genomics SA is a French biotechnology company specializing in the development of new therapies for hypertension and heart failure. The company uses its unique technology platform to develop drugs that interact with the brain in a unique way. Its business model is based on the invention, development, production, and marketing of innovative, novel, and patented medications for the treatment of cardiometabolic diseases. The company focuses on developing its capabilities in research, development, and commercial activities. It aims to sell its innovative technologies and products worldwide through collaboration with local and international leading research centers in cardiometabolic research. With a team of experienced researchers and experts in the pharmaceutical industry, Quantum Genomics is able to bring its products to market quickly and efficiently. The company continuously invests in research and development to improve its technologies and develop new products. It aims to maintain its competitive advantage through the protection of its intellectual property rights and collaboration with other pharmaceutical companies and research organizations. One of Quantum Genomics’ core areas is the research and development of new therapies for hypertension and heart failure. The company has conducted extensive clinical research and developed several drug candidates that interact with the brain in innovative ways, promoting better blood pressure and cardiovascular health. The company has already achieved a significant milestone by successfully gaining approval for its development candidates for clinical trials. Quantum Genomics also has partnerships with other pharmaceutical companies to maximize the potential of its technologies and increase its presence in the market. Through strategic partnerships and licensing agreements, Quantum Genomics aims to market its technology platform worldwide. In addition to its work in cardiometabolic research, Quantum Genomics also has an extensive pipeline of drug candidates for other diseases, such as chronic pain and other psychiatric disorders. The company has already achieved important milestones and established its innovative products in the market. It has strong growth potential and is on a positive path to becoming a key player in the pharmaceutical and biotechnology industry. Overall, Quantum Genomics SA's business model is focused on the development and marketing of innovative therapies for cardiometabolic diseases. The company aims to protect its innovation capabilities and intellectual property rights to strengthen its position in the market and achieve a leadership position in the industry. Quantum Genomics is committed to increasing its presence both in France and internationally and developing partnerships with other pharmaceutical companies to market its technology platform worldwide.

The expected revenue of Quantum Genomics is 283.39 M EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Quantum Genomics is 1.41 B EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Quantum Genomics is currently 0.00. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Quantum Genomics stock.

The price-to-sales ratio (P/S) of Quantum Genomics is currently 0.02. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Quantum Genomics stock.

The Eulerpool Quality Score for Quantum Genomics is 2/10.

The ISIN of Quantum Genomics is FR0011648971. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Quantum Genomics is A1XAEB. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Quantum Genomics is ALQGC.PA. The ticker symbol is used to trade Quantum Genomics shares on the stock exchange.

Quantum Genomics paid dividends every year for the past 0 years.

Quantum Genomics is assigned to the 'Health' sector.

The dividends of Quantum Genomics are distributed in EUR.

All fundamentals and in-depth analysis of Quantum Genomics

Our stock analysis for Quantum Genomics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Quantum Genomics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Quantum Genomics Stock
Quantum Genomics Revenue→
Quantum Genomics Stock
Quantum Genomics Net Income→
Quantum Genomics Stock
Quantum Genomics P/E→
Quantum Genomics Stock
Quantum Genomics P/S→
Quantum Genomics Stock
Quantum Genomics EBIT→
Quantum Genomics Stock
Quantum Genomics Dividend→
Quantum Genomics Stock
Quantum Genomics Directors Dealings→
Quantum Genomics Stock
Quantum Genomics Stocks→
Quantum Genomics Stock
Quantum Genomics Market capitalization→
Quantum Genomics Stock
Quantum Genomics Debt→
Quantum Genomics Stock
Quantum Genomics Liabilities→
Quantum Genomics Stock
Quantum Genomics Equity→
Quantum Genomics Stock
Quantum Genomics AAQS→
Quantum Genomics Stock
Quantum Genomics Employees→
Quantum Genomics Stock
Quantum Genomics ROE→
Quantum Genomics Stock
Quantum Genomics ROA→
Quantum Genomics Stock
Quantum Genomics ROCE→
Quantum Genomics Stock
Quantum Genomics News→
Quantum Genomics Stock
Quantum Genomics Analyst Price Targets→

Health Stocks

Quantum HealthcareQuanterixQuantum Medical TransportQuantaMatrixQuantum-SiQualicorp Consultoria e Corretora de SegurosQuest DiagnosticsQMS Medical Allied ServicesQuest LaboratoriesQlucore publQuest PharmatechQlife HoldingAll Stocks A–Z →